PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 27265009-9 2005 Fibrinogen was only associated with DBP in non-smokers (r= 0.3273, p= 0.0047). Diosmin 36-39 fibrinogen beta chain Homo sapiens 0-10 12698306-1 2003 OBJECTIVE: To screen for inhibitory effects of diosmin on cytochrome P(450)-mediated metabolism of metronidazole in healthy volunteers. Diosmin 47-54 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 58-75 15864129-7 2005 In the logistic regression analyses, compared to subjects with the CT/CT haplotype of the SCNN1G gene, those with the GA/GA haplotype had OR 5.21 of being a DBP responder [95% CI 1.65-16.47]. Diosmin 157-160 sodium channel epithelial 1 subunit gamma Homo sapiens 90-96 15254878-9 2004 The serum TNF-alpha was positively correlated with triglyceride (TG) and DBP, and negatively with high-density lipoprotein-cholesterol (HDLC). Diosmin 73-76 tumor necrosis factor Homo sapiens 10-19 15919838-10 2005 Serum VAP-1 might modulate DBP independently from the changes in insulin resistance in morbidly obese people. Diosmin 27-30 amine oxidase copper containing 3 Homo sapiens 6-11 15343353-9 2004 These results suggest that variants at these two AGT sites together, in conjunction with age, may be significantly associated with elevated SBP, whereas the single-site models are as good models of DBP. Diosmin 198-201 selenium binding protein 1 Homo sapiens 140-143 15127290-3 2004 Linkage evidence with systolic BP (SBP) and diastolic BP (DBP) was observed in a total population of 148 pedigrees with seven flanking microsatellite markers of the LPL gene, with a maximum two-point LOD score of 2.68 and a maximum multipoint LOD score (MLS) of 2.37 for SBP and a maximum MLS of 1.54 for DBP. Diosmin 58-61 lipoprotein lipase Homo sapiens 165-168 12770509-6 2003 On the other hand, serum myeloperoxidase and malondialdehyde levels were significantly lower in the Daflon-received rats (P<0.01, for all). Diosmin 100-106 myeloperoxidase Rattus norvegicus 25-40 12800096-6 2003 The most insulin-resistant tertile of patients exhibited higher body mass index (BMI), androgen levels, systolic and diastolic blood pressure (DBP), triglyceride (TG) levels, and decreased high-density lipoprotein cholesterol (HDL-C) levels. Diosmin 143-146 insulin Homo sapiens 9-16 9163681-8 1997 As for cell proliferation biomarkers, dietary exposure of diosmin and hesperidin significantly decreased the 5"-bromodeoxyuridine-labeling index and argyrophilic nuclear organizer region"s number in crypt cells, colonic mucosal ornithine decarboxylase activity, and polyamine levels in the blood. Diosmin 58-65 ornithine decarboxylase 1 Rattus norvegicus 228-251 12601625-7 2003 However, in hypertensive PHP patients plasma AM levels (22.5 +/- 4.7 pg/mL) were higher than in normotensive PHP patients (11.6 +/- 1.8 pg/mL) (P <.001) and correlated with DBP (r = 0.902, P <.0029). Diosmin 176-179 adrenomedullin Homo sapiens 45-47 9661887-5 1998 Treatment of the cells with diosmin or diosmetin, on the other hand, caused a dose- and time-dependent increase in CYP1A1 activity in intact cells that was comparable to that induced by DMBA or by the aryl hydrocarbon benzo(a)pyrene. Diosmin 28-35 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 115-121 9661887-6 1998 Both diosmin and diosmetin caused an increase in the transcription of the CYP1A1 gene, as measured by increased levels of CYP1A1 mRNA. Diosmin 5-12 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 74-80 9661887-6 1998 Both diosmin and diosmetin caused an increase in the transcription of the CYP1A1 gene, as measured by increased levels of CYP1A1 mRNA. Diosmin 5-12 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 122-128 9661887-8 1998 These results indicate that diosmin and diosmetin are natural dietary agonists of the AhR, causing a potent increase in CYP1A1 transcription and CYP1A1 activity; however, only diosmetin is capable of inhibiting CYP1A1 enzyme activity, thus inhibiting carcinogen activation. Diosmin 28-35 aryl hydrocarbon receptor Homo sapiens 86-89 9661887-8 1998 These results indicate that diosmin and diosmetin are natural dietary agonists of the AhR, causing a potent increase in CYP1A1 transcription and CYP1A1 activity; however, only diosmetin is capable of inhibiting CYP1A1 enzyme activity, thus inhibiting carcinogen activation. Diosmin 28-35 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 120-126 9661887-8 1998 These results indicate that diosmin and diosmetin are natural dietary agonists of the AhR, causing a potent increase in CYP1A1 transcription and CYP1A1 activity; however, only diosmetin is capable of inhibiting CYP1A1 enzyme activity, thus inhibiting carcinogen activation. Diosmin 28-35 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 145-151 9661887-8 1998 These results indicate that diosmin and diosmetin are natural dietary agonists of the AhR, causing a potent increase in CYP1A1 transcription and CYP1A1 activity; however, only diosmetin is capable of inhibiting CYP1A1 enzyme activity, thus inhibiting carcinogen activation. Diosmin 28-35 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 145-151 9661887-0 1998 Diosmin and diosmetin are agonists of the aryl hydrocarbon receptor that differentially affect cytochrome P450 1A1 activity. Diosmin 0-7 aryl hydrocarbon receptor Homo sapiens 42-67 9661887-0 1998 Diosmin and diosmetin are agonists of the aryl hydrocarbon receptor that differentially affect cytochrome P450 1A1 activity. Diosmin 0-7 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 95-114 9661887-1 1998 We investigated the effect of the chemopreventive compound diosmin and its aglycone form, diosmetin, on the carcinogen activation pathway mediated by the aryl hydrocarbon receptor (AhR) in MCF-7 human breast epithelial cancer cells. Diosmin 59-66 aryl hydrocarbon receptor Homo sapiens 154-179 9661887-1 1998 We investigated the effect of the chemopreventive compound diosmin and its aglycone form, diosmetin, on the carcinogen activation pathway mediated by the aryl hydrocarbon receptor (AhR) in MCF-7 human breast epithelial cancer cells. Diosmin 59-66 aryl hydrocarbon receptor Homo sapiens 181-184 8203782-3 1994 Microvascular hyperpermeability induced by bradykinin or ischemia in the rat cremaster muscle was reduced after an oral treatment with Daflon 500 mg (100 mg.kg-1 twice daily). Diosmin 135-141 kininogen 1 Canis lupus familiaris 43-53 8806049-0 1996 In vivo effect of diosmin on carrageenan and CCl4-induced lipid peroxidation in rat liver microsomes. Diosmin 18-25 C-C motif chemokine ligand 4 Rattus norvegicus 45-49 7521474-10 1994 shifted the dose-response curves (DBP and LVdP/dtmax) for AII to the right. Diosmin 34-37 angiotensinogen Rattus norvegicus 58-61 8218608-5 1993 The amount of A II required to raise DBP to over 20 mmHg in AN patients in tests before and after completion of treatment (4.2 +/- 0.33 months later) was significantly different (12.1 +/- 0.47 versus 8.1 +/- 0.25 ng/kg/min, p < 0.01). Diosmin 37-40 angiotensinogen Homo sapiens 14-18 7998672-6 1994 The treatment of rats by intraperitoneal injection of diosmine (150 mg/kg per week) during the 8 weeks which precede the injection of carrageenan or CCl4 results in: i) a marked decrease in the acute-phase reaction and a lower one in the lipoperoxidant effect, in serum; ii) a decrease in the CCl4 induced lipoperoxidant effect in liver microsomes. Diosmin 54-62 C-C motif chemokine ligand 4 Rattus norvegicus 149-153 7998672-6 1994 The treatment of rats by intraperitoneal injection of diosmine (150 mg/kg per week) during the 8 weeks which precede the injection of carrageenan or CCl4 results in: i) a marked decrease in the acute-phase reaction and a lower one in the lipoperoxidant effect, in serum; ii) a decrease in the CCl4 induced lipoperoxidant effect in liver microsomes. Diosmin 54-62 C-C motif chemokine ligand 4 Rattus norvegicus 293-297 33802633-4 2021 Diosmin treatment ameliorated the levels of E2, AMH, and oxidative stress markers. Diosmin 0-7 anti-Mullerian hormone Rattus norvegicus 48-51 1792820-5 1991 Daflon 500 mg decreased: 1) venous capacity (p less than 0.001); 2) venous distensibility (p less than 0.001); and 3) venous outflow time, measured by the two parameters: total emptying venous time (p less than 0.001) and T2p (p less than 0.001). Diosmin 0-6 solute carrier family 25 member 5 Homo sapiens 222-225 34959367-10 2021 CS insolubility and its diffusion layer may explain controlled DSN release from CS-PLX188 NCs. Diosmin 63-66 citrate synthase Rattus norvegicus 0-2 34959367-10 2021 CS insolubility and its diffusion layer may explain controlled DSN release from CS-PLX188 NCs. Diosmin 63-66 citrate synthase Rattus norvegicus 80-82 34461126-8 2021 Natural products like asiatic acid, diosmin, rutin, and so forth have shown significant potential in activating Nrf2 pathway which can lead to attenuate cholestatic liver injury. Diosmin 36-43 NFE2 like bZIP transcription factor 2 Homo sapiens 112-116 34522212-11 2021 Diosmin treatment effectively ameliorated the cognitive disorder and memory deficit of APP/PS1 transgenic mice. Diosmin 0-7 presenilin 1 Mus musculus 91-94 34522212-12 2021 By knocking down AhR or using a small molecular inhibitor targeting AhR or NEP, we found that diosmin enhanced Abeta degradation through activated AhR and increased NEP expression. Diosmin 94-101 aryl-hydrocarbon receptor Mus musculus 17-20 34522212-9 2021 Results: Activating AhR by the endogenous ligand L-Kynurenine (L-KN) or FICZ, or by the exogenous ligand diosmin or indole-3-carbinol (I3C) significantly increases NEP expression and enzyme activity in N2a cells and APP/PS1 mice. Diosmin 105-112 aryl-hydrocarbon receptor Mus musculus 20-23 34522212-9 2021 Results: Activating AhR by the endogenous ligand L-Kynurenine (L-KN) or FICZ, or by the exogenous ligand diosmin or indole-3-carbinol (I3C) significantly increases NEP expression and enzyme activity in N2a cells and APP/PS1 mice. Diosmin 105-112 membrane metallo endopeptidase Mus musculus 164-167 34522212-12 2021 By knocking down AhR or using a small molecular inhibitor targeting AhR or NEP, we found that diosmin enhanced Abeta degradation through activated AhR and increased NEP expression. Diosmin 94-101 aryl-hydrocarbon receptor Mus musculus 68-71 34522212-9 2021 Results: Activating AhR by the endogenous ligand L-Kynurenine (L-KN) or FICZ, or by the exogenous ligand diosmin or indole-3-carbinol (I3C) significantly increases NEP expression and enzyme activity in N2a cells and APP/PS1 mice. Diosmin 105-112 presenilin 1 Mus musculus 220-223 34522212-12 2021 By knocking down AhR or using a small molecular inhibitor targeting AhR or NEP, we found that diosmin enhanced Abeta degradation through activated AhR and increased NEP expression. Diosmin 94-101 membrane metallo endopeptidase Mus musculus 75-78 34522212-12 2021 By knocking down AhR or using a small molecular inhibitor targeting AhR or NEP, we found that diosmin enhanced Abeta degradation through activated AhR and increased NEP expression. Diosmin 94-101 amyloid beta (A4) precursor protein Mus musculus 111-116 34522212-12 2021 By knocking down AhR or using a small molecular inhibitor targeting AhR or NEP, we found that diosmin enhanced Abeta degradation through activated AhR and increased NEP expression. Diosmin 94-101 aryl-hydrocarbon receptor Mus musculus 147-150 34522212-12 2021 By knocking down AhR or using a small molecular inhibitor targeting AhR or NEP, we found that diosmin enhanced Abeta degradation through activated AhR and increased NEP expression. Diosmin 94-101 membrane metallo endopeptidase Mus musculus 165-168 31797688-6 2020 It was found that diosmin at the doses of 20 and 40 mg kg-1 significantly reduced malondialdehyde and xanthine oxidase formation in a dose-dependent manner; however, it replenished catalase, glutathione (GSH), and GSH-dependent enzymes, that is, glutathione peroxidase, glutathione reductase, and glutathione-S-transferase significantly against TP-induced BPH. Diosmin 18-25 glutathione-disulfide reductase Rattus norvegicus 270-291 34100397-0 2021 Therapeutic potential of diosmin, a citrus flavonoid against arsenic-induced neurotoxicity via suppression of NOX 4 and its subunits. Diosmin 25-32 NADPH oxidase 4 Homo sapiens 110-115 34100397-10 2021 Immunohistochemical studies have revealed the expression of NOX4 and its gp91phox and P47phox subunits and its suppression by DSN treatment may be the key therapeutic factor of it. Diosmin 126-129 NADPH oxidase 4 Homo sapiens 60-64 34100397-10 2021 Immunohistochemical studies have revealed the expression of NOX4 and its gp91phox and P47phox subunits and its suppression by DSN treatment may be the key therapeutic factor of it. Diosmin 126-129 cytochrome b-245 beta chain Homo sapiens 73-81 34100397-10 2021 Immunohistochemical studies have revealed the expression of NOX4 and its gp91phox and P47phox subunits and its suppression by DSN treatment may be the key therapeutic factor of it. Diosmin 126-129 neutrophil cytosolic factor 1 Homo sapiens 86-93 34100397-11 2021 Conclusions: Treatment with DSN showed a beneficial effect in protecting against arsenic-induced neurotoxicity by suppressing the toxicity changes and the antioxidant effect of DSN might be attributed to its ability of suppressing NOX4 and its subunits. Diosmin 28-31 NADPH oxidase 4 Homo sapiens 231-235 34100397-11 2021 Conclusions: Treatment with DSN showed a beneficial effect in protecting against arsenic-induced neurotoxicity by suppressing the toxicity changes and the antioxidant effect of DSN might be attributed to its ability of suppressing NOX4 and its subunits. Diosmin 177-180 NADPH oxidase 4 Homo sapiens 231-235 35364308-6 2022 Our obtained result demonstrate that Hesperidin, rutin, diosmin, and apiin are most effective compounds agents against SARS-CoV-2 Mpro as compared to Nelfinavir (positive control). Diosmin 56-63 NEWENTRY Severe acute respiratory syndrome-related coronavirus 130-134 3789890-0 1986 Comparative effect of tropolone and diosmin on venous COMT and sympathetic activity in rat. Diosmin 36-43 catechol-O-methyltransferase Rattus norvegicus 54-58 3789890-1 1986 The ability of diosmin to inhibit venous catechol-O-methyltransferase (COMT) activity was studied comparing it with tropolone in rat superior mesenteric vein (MV), inferior vena cava (IVC) and saphenous vein (SV). Diosmin 15-22 catechol-O-methyltransferase Rattus norvegicus 41-69 3789890-1 1986 The ability of diosmin to inhibit venous catechol-O-methyltransferase (COMT) activity was studied comparing it with tropolone in rat superior mesenteric vein (MV), inferior vena cava (IVC) and saphenous vein (SV). Diosmin 15-22 catechol-O-methyltransferase Rattus norvegicus 71-75 3789890-2 1986 Diosmin inhibited COMT activity in the mesenteric vein after 200 and 400 mg/kg i.p., but only at 400 mg/kg in IVC. Diosmin 0-7 catechol-O-methyltransferase Rattus norvegicus 18-22 3789890-3 1986 The COMT inhibitory effect of diosmin (400 mg/kg) was smaller than that of tropolone (50 mg/kg). Diosmin 30-37 catechol-O-methyltransferase Rattus norvegicus 4-8 33744325-15 2021 SIGNIFICANCE: DS could be a promising protective agent against GM-induced nephrotoxicity through targeting of KEAP1/Nrf2/ARE, AKT, and PPAR-gamma signaling pathways. Diosmin 14-16 Kelch-like ECH-associated protein 1 Rattus norvegicus 110-115 33744325-15 2021 SIGNIFICANCE: DS could be a promising protective agent against GM-induced nephrotoxicity through targeting of KEAP1/Nrf2/ARE, AKT, and PPAR-gamma signaling pathways. Diosmin 14-16 NFE2 like bZIP transcription factor 2 Rattus norvegicus 116-120 33744325-15 2021 SIGNIFICANCE: DS could be a promising protective agent against GM-induced nephrotoxicity through targeting of KEAP1/Nrf2/ARE, AKT, and PPAR-gamma signaling pathways. Diosmin 14-16 AKT serine/threonine kinase 1 Rattus norvegicus 126-129 33744325-15 2021 SIGNIFICANCE: DS could be a promising protective agent against GM-induced nephrotoxicity through targeting of KEAP1/Nrf2/ARE, AKT, and PPAR-gamma signaling pathways. Diosmin 14-16 peroxisome proliferator-activated receptor gamma Rattus norvegicus 135-145 33847241-7 2021 Thereafter, we performed ensemble-based virtual screening by exploiting the ZINC and DrugBank databases and identified three candidate molecules, namely eluxadoline, diosmin, and ZINC02948810 that could invoke local and global conformational rearrangements which were also elicited by alpha-ketoamide 13b on the catalytic dyad of Mpro. Diosmin 166-173 NEWENTRY Severe acute respiratory syndrome-related coronavirus 330-334 32208122-10 2021 CONCLUSION: From the result it was concluded that diosmin was a potentially inhibitor of aldose reductase, alpha amylase and alpha glucosidase enzymes then the standard drugs and it will be helpful in the management of diabetes and its complications. Diosmin 50-57 aldo-keto reductase family 1 member B Homo sapiens 89-105 33302042-14 2021 Immunofluorescence results showed that diosmin stimulated AhR nuclear translocation, and the drug affinity responsive target stability assay revealed that this phytochemical directly bound to AhR. Diosmin 39-46 aryl hydrocarbon receptor Homo sapiens 58-61 33302042-16 2021 CONCLUSION: These results suggest that diosmin is a potential treatment for AD that targets AhR. Diosmin 39-46 aryl hydrocarbon receptor Homo sapiens 92-95 35477428-8 2022 We further confirmed that diosmin blunted oxidative stress-, inflammation-, apoptosis-, and autophagy-related factors expression induced by HG via restraining the CHOP and GRP78 expressions. Diosmin 26-33 DNA damage inducible transcript 3 Homo sapiens 163-167 35477428-8 2022 We further confirmed that diosmin blunted oxidative stress-, inflammation-, apoptosis-, and autophagy-related factors expression induced by HG via restraining the CHOP and GRP78 expressions. Diosmin 26-33 heat shock protein family A (Hsp70) member 5 Homo sapiens 172-177 35477428-10 2022 CONCLUSIONS: Our study manifested that diosmin alleviated the HG-mediated endoplasmic reticulum stress injury in HK-2 cells via restraining the PI3K/AKT pathway. Diosmin 39-46 AKT serine/threonine kinase 1 Homo sapiens 149-152 2698902-4 1989 In this study, which included 20 patients suffering from post-thrombotic syndrome, Daflon 500 mg decreased: 1) venous capacity (p less than 0.001); 2) venous distensibility (p less than 0.001); 3) venous outflow time, measured by the two parameters total emptying venous time (p less than 0.001) and T2p (p less than 0.001). Diosmin 83-89 solute carrier family 25 member 5 Homo sapiens 300-303 33744325-0 2021 Targeting KEAP1/Nrf2, AKT, and PPAR-gamma signals as a potential protective mechanism of diosmin against gentamicin-induced nephrotoxicity. Diosmin 89-96 Kelch-like ECH-associated protein 1 Rattus norvegicus 10-15 33744325-0 2021 Targeting KEAP1/Nrf2, AKT, and PPAR-gamma signals as a potential protective mechanism of diosmin against gentamicin-induced nephrotoxicity. Diosmin 89-96 NFE2 like bZIP transcription factor 2 Rattus norvegicus 16-20 33744325-0 2021 Targeting KEAP1/Nrf2, AKT, and PPAR-gamma signals as a potential protective mechanism of diosmin against gentamicin-induced nephrotoxicity. Diosmin 89-96 AKT serine/threonine kinase 1 Rattus norvegicus 22-25 33744325-0 2021 Targeting KEAP1/Nrf2, AKT, and PPAR-gamma signals as a potential protective mechanism of diosmin against gentamicin-induced nephrotoxicity. Diosmin 89-96 peroxisome proliferator-activated receptor gamma Rattus norvegicus 31-41 33744325-10 2021 In addition, co-treatment with DS plus GM significantly enhanced Nrf2, GCLC, HO-1, SOD3, AKT, and p-AKT expressions along with KEAP1 down-regulation. Diosmin 31-33 NFE2 like bZIP transcription factor 2 Rattus norvegicus 65-69 33744325-10 2021 In addition, co-treatment with DS plus GM significantly enhanced Nrf2, GCLC, HO-1, SOD3, AKT, and p-AKT expressions along with KEAP1 down-regulation. Diosmin 31-33 glutamate-cysteine ligase, catalytic subunit Rattus norvegicus 71-75 33744325-10 2021 In addition, co-treatment with DS plus GM significantly enhanced Nrf2, GCLC, HO-1, SOD3, AKT, and p-AKT expressions along with KEAP1 down-regulation. Diosmin 31-33 heme oxygenase 1 Rattus norvegicus 77-81 33744325-10 2021 In addition, co-treatment with DS plus GM significantly enhanced Nrf2, GCLC, HO-1, SOD3, AKT, and p-AKT expressions along with KEAP1 down-regulation. Diosmin 31-33 superoxide dismutase 3 Rattus norvegicus 83-87 33744325-10 2021 In addition, co-treatment with DS plus GM significantly enhanced Nrf2, GCLC, HO-1, SOD3, AKT, and p-AKT expressions along with KEAP1 down-regulation. Diosmin 31-33 AKT serine/threonine kinase 1 Rattus norvegicus 89-92 33744325-10 2021 In addition, co-treatment with DS plus GM significantly enhanced Nrf2, GCLC, HO-1, SOD3, AKT, and p-AKT expressions along with KEAP1 down-regulation. Diosmin 31-33 AKT serine/threonine kinase 1 Rattus norvegicus 100-103 33744325-10 2021 In addition, co-treatment with DS plus GM significantly enhanced Nrf2, GCLC, HO-1, SOD3, AKT, and p-AKT expressions along with KEAP1 down-regulation. Diosmin 31-33 Kelch-like ECH-associated protein 1 Rattus norvegicus 127-132 33744325-14 2021 Interestingly, in-silico results strongly supported our biochemical investigation by studying the binding affinity of DS to KEAP1, AKT, and PPAR-gamma proteins. Diosmin 118-120 Kelch-like ECH-associated protein 1 Rattus norvegicus 124-129 33744325-14 2021 Interestingly, in-silico results strongly supported our biochemical investigation by studying the binding affinity of DS to KEAP1, AKT, and PPAR-gamma proteins. Diosmin 118-120 AKT serine/threonine kinase 1 Rattus norvegicus 131-134 33744325-14 2021 Interestingly, in-silico results strongly supported our biochemical investigation by studying the binding affinity of DS to KEAP1, AKT, and PPAR-gamma proteins. Diosmin 118-120 peroxisome proliferator-activated receptor gamma Rattus norvegicus 140-150 32938818-7 2020 Diosmetin or diosmin treatment also reduced IgE and IL-4 levels in AD-induced hairless mouse serum samples. Diosmin 13-20 interleukin 4 Mus musculus 52-56 31797688-7 2020 Further, immunohistochemical study showed that diosmin alleviated inflammatory markers (nuclear factor kappa-light-chain-enhancer of activated B cells, cyclooxygenase-2, and interleukin-6). Diosmin 47-54 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 152-168 31797688-7 2020 Further, immunohistochemical study showed that diosmin alleviated inflammatory markers (nuclear factor kappa-light-chain-enhancer of activated B cells, cyclooxygenase-2, and interleukin-6). Diosmin 47-54 interleukin 6 Rattus norvegicus 174-187 31797688-8 2020 It was also found that diosmin downregulated the expression of androgen receptor and decreased the prostate-specific antigen concentration dose-dependently, significantly against TP-induced BPH. Diosmin 23-30 androgen receptor Rattus norvegicus 63-80 32512072-9 2020 Treatment with diosmin demonstrated multiple beneficial effects as it significantly ameliorated histopathological NASH findings, lowered TNF-alpha, interleukin-6, and malondialdehyde levels, improved lipid and glucose metabolism, and lowered hepatic TGF-beta, alpha-SMA, and collagen content compared to untreated rats. Diosmin 15-22 tumor necrosis factor Rattus norvegicus 137-146 32512072-9 2020 Treatment with diosmin demonstrated multiple beneficial effects as it significantly ameliorated histopathological NASH findings, lowered TNF-alpha, interleukin-6, and malondialdehyde levels, improved lipid and glucose metabolism, and lowered hepatic TGF-beta, alpha-SMA, and collagen content compared to untreated rats. Diosmin 15-22 interleukin 6 Rattus norvegicus 148-161 32512072-9 2020 Treatment with diosmin demonstrated multiple beneficial effects as it significantly ameliorated histopathological NASH findings, lowered TNF-alpha, interleukin-6, and malondialdehyde levels, improved lipid and glucose metabolism, and lowered hepatic TGF-beta, alpha-SMA, and collagen content compared to untreated rats. Diosmin 15-22 transforming growth factor alpha Rattus norvegicus 250-258 32460808-7 2020 Administration of AES and/or DIO significantly reversed all those CCl4-induced effects. Diosmin 29-32 C-C motif chemokine ligand 4 Rattus norvegicus 66-70 32083866-4 2020 Here we investigated the efficacy of diosmin in a nonsterile model of inflammatory pain and peritonitis induced by LPS. Diosmin 37-44 toll-like receptor 4 Mus musculus 115-118 31481696-7 2020 The level of miR-155 was positively correlated with C-reactive protein, interleukin-6, office systolic blood pressure (SBP), and diastolic blood pressure (DBP), and ABMP parameters (24-h SBP, 24-h DBP, 24-h daytime SBP, 24-h daytime DBP, 24-h nighttime SBP and 24 h nighttime DBP) (all P < 0.05). Diosmin 155-158 microRNA 155 Homo sapiens 13-20 31481696-7 2020 The level of miR-155 was positively correlated with C-reactive protein, interleukin-6, office systolic blood pressure (SBP), and diastolic blood pressure (DBP), and ABMP parameters (24-h SBP, 24-h DBP, 24-h daytime SBP, 24-h daytime DBP, 24-h nighttime SBP and 24 h nighttime DBP) (all P < 0.05). Diosmin 197-200 microRNA 155 Homo sapiens 13-20 32205046-3 2020 Using this efficient assay system a chemical library of 2000 bioactive compounds was screened against IKKbeta and four were identified as good inhibitors, namely, aurintricarboxylic acid, diosmin, ellagic acid, and hematein. Diosmin 188-195 component of inhibitor of nuclear factor kappa B kinase complex Homo sapiens 102-109 32083866-5 2020 Diosmin reduced in a dose-dependent manner LPS-induced inflammatory mechanical hyperalgesia, thermal hyperalgesia, and neutrophil recruitment to the paw (myeloperoxidase activity). Diosmin 0-7 toll-like receptor 4 Mus musculus 43-46 32083866-7 2020 Moreover, treatment with diosmin inhibited LPS-induced peritonitis as observed by a reduction of leukocyte recruitment and oxidative stress. Diosmin 25-32 toll-like receptor 4 Mus musculus 43-46 32083866-8 2020 Diosmin reduced LPS-induced total ROS production (DCFDA assay) and superoxide anion production (NBT assay and NBT-positive cells). Diosmin 0-7 toll-like receptor 4 Mus musculus 16-19 32083866-10 2020 Furthermore, we demonstrated that diosmin inhibited LPS-induced NF-kappaB activation in peritoneal exudate. Diosmin 34-41 toll-like receptor 4 Mus musculus 52-55 32083866-11 2020 Thus, we demonstrated, using a model of nonsterile inflammation induced by LPS, that diosmin is a promising molecule for the treatment of inflammation and pain. Diosmin 85-92 toll-like receptor 4 Mus musculus 75-78 32050083-12 2020 Collectively, DS can augment the anti-angiogenic activity of Sild and PTX during HPS through regulation of TNF-alpha/VEGF, IGF-1/PI3K/AKT, and FGF-1/ANG-2 signaling pathways. Diosmin 14-16 tumor necrosis factor Rattus norvegicus 107-116 32050083-12 2020 Collectively, DS can augment the anti-angiogenic activity of Sild and PTX during HPS through regulation of TNF-alpha/VEGF, IGF-1/PI3K/AKT, and FGF-1/ANG-2 signaling pathways. Diosmin 14-16 vascular endothelial growth factor A Rattus norvegicus 117-121 32050083-12 2020 Collectively, DS can augment the anti-angiogenic activity of Sild and PTX during HPS through regulation of TNF-alpha/VEGF, IGF-1/PI3K/AKT, and FGF-1/ANG-2 signaling pathways. Diosmin 14-16 insulin-like growth factor 1 Rattus norvegicus 123-128 32050083-12 2020 Collectively, DS can augment the anti-angiogenic activity of Sild and PTX during HPS through regulation of TNF-alpha/VEGF, IGF-1/PI3K/AKT, and FGF-1/ANG-2 signaling pathways. Diosmin 14-16 AKT serine/threonine kinase 1 Rattus norvegicus 134-137 32050083-12 2020 Collectively, DS can augment the anti-angiogenic activity of Sild and PTX during HPS through regulation of TNF-alpha/VEGF, IGF-1/PI3K/AKT, and FGF-1/ANG-2 signaling pathways. Diosmin 14-16 fibroblast growth factor 1 Rattus norvegicus 143-148 32050083-12 2020 Collectively, DS can augment the anti-angiogenic activity of Sild and PTX during HPS through regulation of TNF-alpha/VEGF, IGF-1/PI3K/AKT, and FGF-1/ANG-2 signaling pathways. Diosmin 14-16 angiogenin, ribonuclease A family, member 2 Rattus norvegicus 149-154 32088816-0 2020 The synergistic anti-proliferative effect of the combination of diosmin and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line occurs through inhibition of the PI3K/Akt/mTOR/NF-kappaB axis. Diosmin 64-71 AKT serine/threonine kinase 1 Homo sapiens 178-181 32088816-0 2020 The synergistic anti-proliferative effect of the combination of diosmin and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line occurs through inhibition of the PI3K/Akt/mTOR/NF-kappaB axis. Diosmin 64-71 mechanistic target of rapamycin kinase Homo sapiens 182-186 32088816-0 2020 The synergistic anti-proliferative effect of the combination of diosmin and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line occurs through inhibition of the PI3K/Akt/mTOR/NF-kappaB axis. Diosmin 64-71 nuclear factor kappa B subunit 1 Homo sapiens 187-196 32088816-5 2020 Hence, we aimed to evaluate the potential long-lasting anti-carcinogenic effects of adding diosmin (DIO, a natural NF-kappaB inhibitor) to BEZ-235 in HCT-116 CRC cells. Diosmin 91-98 nuclear factor kappa B subunit 1 Homo sapiens 115-124 31534190-6 2020 The mean (+-standard deviation: SD) differences in systolic BP (SBP) and diastolic BP (DBP) between the methods were -0.7 +- 7.1 and -1.1 +- 4.5 mmHg, respectively, and those for each participant were -0.7 +- 5.8 mmHg for SBP and -1.1 +- 4.1 mmHg for DBP; the device therefore fulfilled the requirements of the ISO protocol. Diosmin 87-90 selenium binding protein 1 Homo sapiens 51-85 31902439-7 2020 Moreover, diosmin increased plasma insulin and c-peptide levels, cardiac glutathione content, superoxide dismutase, catalase and glutathione S-transferase activities. Diosmin 10-17 insulin 2 Rattus norvegicus 47-56 31902439-7 2020 Moreover, diosmin increased plasma insulin and c-peptide levels, cardiac glutathione content, superoxide dismutase, catalase and glutathione S-transferase activities. Diosmin 10-17 catalase Rattus norvegicus 116-124 31902439-7 2020 Moreover, diosmin increased plasma insulin and c-peptide levels, cardiac glutathione content, superoxide dismutase, catalase and glutathione S-transferase activities. Diosmin 10-17 hematopoietic prostaglandin D synthase Rattus norvegicus 129-154 31902439-8 2020 Also, diosmin treatment significantly (P < 0.05) lowered the levels of interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), down-regulated cardiac Bcl-2-associated X protein and caspase 3 and 9 and up-regulated B-cell lymphoma 2 mRNA expression levels. Diosmin 6-13 interleukin 1 beta Rattus norvegicus 74-91 31902439-8 2020 Also, diosmin treatment significantly (P < 0.05) lowered the levels of interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), down-regulated cardiac Bcl-2-associated X protein and caspase 3 and 9 and up-regulated B-cell lymphoma 2 mRNA expression levels. Diosmin 6-13 interleukin 1 beta Rattus norvegicus 93-101 31902439-8 2020 Also, diosmin treatment significantly (P < 0.05) lowered the levels of interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), down-regulated cardiac Bcl-2-associated X protein and caspase 3 and 9 and up-regulated B-cell lymphoma 2 mRNA expression levels. Diosmin 6-13 interleukin 6 Rattus norvegicus 104-117 31902439-8 2020 Also, diosmin treatment significantly (P < 0.05) lowered the levels of interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), down-regulated cardiac Bcl-2-associated X protein and caspase 3 and 9 and up-regulated B-cell lymphoma 2 mRNA expression levels. Diosmin 6-13 interleukin 6 Rattus norvegicus 119-123 31902439-8 2020 Also, diosmin treatment significantly (P < 0.05) lowered the levels of interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), down-regulated cardiac Bcl-2-associated X protein and caspase 3 and 9 and up-regulated B-cell lymphoma 2 mRNA expression levels. Diosmin 6-13 tumor necrosis factor Rattus norvegicus 129-156 31902439-8 2020 Also, diosmin treatment significantly (P < 0.05) lowered the levels of interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), down-regulated cardiac Bcl-2-associated X protein and caspase 3 and 9 and up-regulated B-cell lymphoma 2 mRNA expression levels. Diosmin 6-13 tumor necrosis factor Rattus norvegicus 158-167 31902439-8 2020 Also, diosmin treatment significantly (P < 0.05) lowered the levels of interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), down-regulated cardiac Bcl-2-associated X protein and caspase 3 and 9 and up-regulated B-cell lymphoma 2 mRNA expression levels. Diosmin 6-13 caspase 3 Rattus norvegicus 224-239 31547271-6 2019 The average content of TNF alpha, VEGF-C, VEGF-A IL-6, and FGF2 decreased after the therapy with diosmin in a significant manner; with p < 0.001, p < 0.05, p < 0.05, p < 0.01, and p < 0.01, respectively, and a significant (p < 0.05) increase in the plasma angiostatin level after the three-month treatment was found. Diosmin 97-104 tumor necrosis factor Homo sapiens 23-32 31800712-7 2019 Vimentin immunostaining showed that diosmin induced morphological changes in GBM95 and GBM02 cells, making them smaller and more polygonal. Diosmin 36-43 vimentin Homo sapiens 0-8 31547271-6 2019 The average content of TNF alpha, VEGF-C, VEGF-A IL-6, and FGF2 decreased after the therapy with diosmin in a significant manner; with p < 0.001, p < 0.05, p < 0.05, p < 0.01, and p < 0.01, respectively, and a significant (p < 0.05) increase in the plasma angiostatin level after the three-month treatment was found. Diosmin 97-104 vascular endothelial growth factor C Homo sapiens 34-40 31547271-6 2019 The average content of TNF alpha, VEGF-C, VEGF-A IL-6, and FGF2 decreased after the therapy with diosmin in a significant manner; with p < 0.001, p < 0.05, p < 0.05, p < 0.01, and p < 0.01, respectively, and a significant (p < 0.05) increase in the plasma angiostatin level after the three-month treatment was found. Diosmin 97-104 vascular endothelial growth factor A Homo sapiens 42-48 31547271-6 2019 The average content of TNF alpha, VEGF-C, VEGF-A IL-6, and FGF2 decreased after the therapy with diosmin in a significant manner; with p < 0.001, p < 0.05, p < 0.05, p < 0.01, and p < 0.01, respectively, and a significant (p < 0.05) increase in the plasma angiostatin level after the three-month treatment was found. Diosmin 97-104 interleukin 6 Homo sapiens 49-53 31547271-6 2019 The average content of TNF alpha, VEGF-C, VEGF-A IL-6, and FGF2 decreased after the therapy with diosmin in a significant manner; with p < 0.001, p < 0.05, p < 0.05, p < 0.01, and p < 0.01, respectively, and a significant (p < 0.05) increase in the plasma angiostatin level after the three-month treatment was found. Diosmin 97-104 fibroblast growth factor 2 Homo sapiens 59-63 29091880-11 2018 The anti-hyperalgesic effects of diosmin were also linked with reduced levels of TNF-alpha, IL-1beta and IL-6. Diosmin 33-40 interleukin 6 Rattus norvegicus 105-109 31434256-4 2019 Five flavonoid glycosides were identified as eriocitrin, narirutin, hesperidin, rutin, and diosmin according to the molecular formula provided by TOF/MS and subsequent confirmation of the authentic standard. Diosmin 91-98 FEZ family zinc finger 2 Homo sapiens 146-149 31177049-3 2019 In this study, metabolites of diosmin and diosmetin were identified using an UHPLC-LTQ-Orbitrap MSn strategy coupled with multiple metabolite templates, extracted ion chromatograms (EICs) and diagnostic product ions (DPIs). Diosmin 30-37 moesin Rattus norvegicus 96-99 31241043-5 2019 Our study showed that especially high concentrations of diosmin decreased NO, PGE2, IL-6, IL-12, TNF-alpha production and mRNA levels of these mediators (p < 0.05). Diosmin 56-63 interleukin 6 Homo sapiens 84-88 31241043-5 2019 Our study showed that especially high concentrations of diosmin decreased NO, PGE2, IL-6, IL-12, TNF-alpha production and mRNA levels of these mediators (p < 0.05). Diosmin 56-63 tumor necrosis factor Homo sapiens 97-106 31241043-6 2019 The expression of phosphorylated-JNK was significantly suppressed by diosmin at 40 and 50 microM concentrations. Diosmin 69-76 mitogen-activated protein kinase 8 Homo sapiens 33-36 31241043-7 2019 Furthermore, diosmin significantly inhibited the expression of phosphorylated-ERK, p38, and p-IkappaB-alpha in a dose-dependent manner. Diosmin 13-20 mitogen-activated protein kinase 1 Homo sapiens 78-81 31241043-7 2019 Furthermore, diosmin significantly inhibited the expression of phosphorylated-ERK, p38, and p-IkappaB-alpha in a dose-dependent manner. Diosmin 13-20 mitogen-activated protein kinase 14 Homo sapiens 83-86 31241043-7 2019 Furthermore, diosmin significantly inhibited the expression of phosphorylated-ERK, p38, and p-IkappaB-alpha in a dose-dependent manner. Diosmin 13-20 NFKB inhibitor alpha Homo sapiens 94-107 30203575-7 2018 RESULTS: In the substance P-induced inflammation model, 2% diosmin cream exhibited significant vasoconstrictive (proportion of dilated capillaries: -29%, capillary luminal area: -49% vs no cream + stress) and anti-inflammatory (IL-8 release: -36% vs no cream + stress) effects. Diosmin 59-66 tachykinin precursor 1 Homo sapiens 16-27 30203575-7 2018 RESULTS: In the substance P-induced inflammation model, 2% diosmin cream exhibited significant vasoconstrictive (proportion of dilated capillaries: -29%, capillary luminal area: -49% vs no cream + stress) and anti-inflammatory (IL-8 release: -36% vs no cream + stress) effects. Diosmin 59-66 C-X-C motif chemokine ligand 8 Homo sapiens 228-232 30033401-2 2018 This study designed to investigate the relation of daflon with hyaluronan as a mediator for the hepatoprotective effect against Carbon tetrachloride (CCl4) and/or gamma-radiation induced liver damage. Diosmin 51-57 C-C motif chemokine ligand 4 Rattus norvegicus 150-154 29479636-4 2018 The oral administration of diosmin as a protective agent normalized the altered levels of AFP, LPO, antioxidant enzymes, pro- and anti-apoptotic proteins as well as caspase-3 and -9 proteins. Diosmin 27-34 alpha-fetoprotein Rattus norvegicus 90-93 29479636-4 2018 The oral administration of diosmin as a protective agent normalized the altered levels of AFP, LPO, antioxidant enzymes, pro- and anti-apoptotic proteins as well as caspase-3 and -9 proteins. Diosmin 27-34 caspase 3 Rattus norvegicus 165-181 30026087-11 2018 It can be concluded that, DS and sildenafil exhibit hepatoprotective effects through modulation of Keap-1/Nrf-2 and P38-MAPK/NF-kappaB/iNOS pathway. Diosmin 26-28 kelch like ECH associated protein 1 Homo sapiens 99-105 30026087-11 2018 It can be concluded that, DS and sildenafil exhibit hepatoprotective effects through modulation of Keap-1/Nrf-2 and P38-MAPK/NF-kappaB/iNOS pathway. Diosmin 26-28 NFE2 like bZIP transcription factor 2 Homo sapiens 106-111 30026087-11 2018 It can be concluded that, DS and sildenafil exhibit hepatoprotective effects through modulation of Keap-1/Nrf-2 and P38-MAPK/NF-kappaB/iNOS pathway. Diosmin 26-28 mitogen-activated protein kinase 14 Homo sapiens 116-119 30026087-11 2018 It can be concluded that, DS and sildenafil exhibit hepatoprotective effects through modulation of Keap-1/Nrf-2 and P38-MAPK/NF-kappaB/iNOS pathway. Diosmin 26-28 nuclear factor kappa B subunit 1 Homo sapiens 125-134 30026087-11 2018 It can be concluded that, DS and sildenafil exhibit hepatoprotective effects through modulation of Keap-1/Nrf-2 and P38-MAPK/NF-kappaB/iNOS pathway. Diosmin 26-28 inositol-3-phosphate synthase 1 Homo sapiens 135-139 29852187-0 2018 Targeting Keap-1/Nrf-2 pathway and cytoglobin as a potential protective mechanism of diosmin and pentoxifylline against cholestatic liver cirrhosis. Diosmin 85-92 Kelch-like ECH-associated protein 1 Rattus norvegicus 10-16 29852187-0 2018 Targeting Keap-1/Nrf-2 pathway and cytoglobin as a potential protective mechanism of diosmin and pentoxifylline against cholestatic liver cirrhosis. Diosmin 85-92 NFE2 like bZIP transcription factor 2 Rattus norvegicus 17-22 29852187-0 2018 Targeting Keap-1/Nrf-2 pathway and cytoglobin as a potential protective mechanism of diosmin and pentoxifylline against cholestatic liver cirrhosis. Diosmin 85-92 cytoglobin Rattus norvegicus 35-45 29852187-10 2018 SIGNIFICANCE: DS and PTX could mitigate liver cirrhosis through modulation of Keap-1/Nrf-2/GSH and NF-kappaB-p65/p38-MAPK signaling pathways. Diosmin 14-16 Kelch-like ECH-associated protein 1 Rattus norvegicus 78-84 29852187-10 2018 SIGNIFICANCE: DS and PTX could mitigate liver cirrhosis through modulation of Keap-1/Nrf-2/GSH and NF-kappaB-p65/p38-MAPK signaling pathways. Diosmin 14-16 NFE2 like bZIP transcription factor 2 Rattus norvegicus 85-90 29852187-10 2018 SIGNIFICANCE: DS and PTX could mitigate liver cirrhosis through modulation of Keap-1/Nrf-2/GSH and NF-kappaB-p65/p38-MAPK signaling pathways. Diosmin 14-16 synaptotagmin 1 Rattus norvegicus 109-112 29852187-10 2018 SIGNIFICANCE: DS and PTX could mitigate liver cirrhosis through modulation of Keap-1/Nrf-2/GSH and NF-kappaB-p65/p38-MAPK signaling pathways. Diosmin 14-16 mitogen activated protein kinase 14 Rattus norvegicus 113-116 29852187-11 2018 In addition, we demonstrated that the hepatoprotective effect of DS and PTX is mediated by up-regulation of cytoglobin with inhibition of fibrotic reaction. Diosmin 65-67 cytoglobin Rattus norvegicus 108-118 29134244-0 2018 Modulation of CYP3A enzyme activity by diosmin and its consequence on carbamazepine pharmacokinetics in rats. Diosmin 39-46 cytochrome P450, family 3, subfamily a, polypeptide 62 Rattus norvegicus 14-19 29134244-4 2018 Diosmin-mediated altered CYP3A enzyme activity in human and rat liver microsomes was examined using CYP3A dependent erythromycin N-demethylase assay. Diosmin 0-7 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 25-30 29134244-4 2018 Diosmin-mediated altered CYP3A enzyme activity in human and rat liver microsomes was examined using CYP3A dependent erythromycin N-demethylase assay. Diosmin 0-7 cytochrome P450, family 3, subfamily a, polypeptide 62 Rattus norvegicus 100-105 29134244-6 2018 The CYP3A enzyme activity in human and rat liver microsomes was significantly (p < 0.05) decreased by diosmin when compared to control. Diosmin 105-112 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 4-9 29134244-10 2018 The results suggest that diosmin pretreatment might have inhibited CYP3A-mediated metabolism of CBZ. Diosmin 25-32 cytochrome P450, family 3, subfamily a, polypeptide 62 Rattus norvegicus 67-72 29688202-1 2018 The purpose of the study was to evaluate efficacy of Diosmin (Phlebodia 600, Innothera, France) in treatment of patients presenting with class C0s-C3 chronic venous diseases (CVD) according to the CEAP classification. Diosmin 53-60 biogenesis of lysosomal organelles complex 1 subunit 2 Homo sapiens 197-201 29091880-11 2018 The anti-hyperalgesic effects of diosmin were also linked with reduced levels of TNF-alpha, IL-1beta and IL-6. Diosmin 33-40 tumor necrosis factor Rattus norvegicus 81-90 29091880-11 2018 The anti-hyperalgesic effects of diosmin were also linked with reduced levels of TNF-alpha, IL-1beta and IL-6. Diosmin 33-40 interleukin 1 beta Rattus norvegicus 92-100 29141968-8 2017 A weak effect size was observed in a meta-analysis of trials that used NO3-depleted beetroot juice as a placebo compared with other interventions (-3.09 compared with -4.51 mm Hg for SBP and -0.81 compared with -2.01 mm Hg for DBP). Diosmin 227-230 NBL1, DAN family BMP antagonist Homo sapiens 71-74 29258224-8 2017 Furthermore, diosmin could abrogate high glucose-induced apoptosis as well as JNK and P38 MAPK phosphorylation in ARPE-19 cells. Diosmin 13-20 mitogen-activated protein kinase 8 Homo sapiens 78-81 29183297-8 2017 RESULTS: The risk increased by 4% and 39% per each 10 mmHg and 1 mmol/L increase in SBP/DBP and TC, respectively; additionally, females had a 70% lower risk. Diosmin 88-91 selenium binding protein 1 Homo sapiens 84-87 29187079-11 2018 Also, DIO resulted in significant reduction of inflammatory and oxidative stress markers as well as reduced the expression of caspase-3. Diosmin 6-9 caspase 3 Rattus norvegicus 126-135 28625489-9 2017 Single treatment with diosmin inhibited in a dose-dependent manner CCI-induced mechanical and thermal hyperalgesia by activating the NO/cGMP/PKG/KATP channel signaling pathway and inhibiting spinal cord cytokine (Il-1beta and Il-33/St2) and glial cells activation (microglia - Iba-1, oligodendrocytes - Olig2) mRNA expression markers. Diosmin 22-29 interleukin 1 beta Mus musculus 213-221 28639612-12 2017 RBP4 level was positively correlated with BMI (r=0.226, P=0.001), SBP (r=0.468, P<0.001) and DBP (r=0.358, P<0.001) after adjustment for age, sex, smoking status and alcohol consumption. Diosmin 96-99 retinol binding protein 4 Homo sapiens 0-4 27690733-2 2017 Carbamazepine (CBZ) is an antiepileptic drug with narrow therapeutic window and administration in humans receiving long-term therapy with diosmin (DSN) may occur, which leads to CYP3A4-mediated drug interactions. Diosmin 138-145 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 178-184 27690733-2 2017 Carbamazepine (CBZ) is an antiepileptic drug with narrow therapeutic window and administration in humans receiving long-term therapy with diosmin (DSN) may occur, which leads to CYP3A4-mediated drug interactions. Diosmin 147-150 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 178-184 27690733-14 2017 The results suggest that the altered CYP3A4 enzyme activity and pharmacokinetics of CBZ might be attributed to DSN-mediated inhibition of CYP3A4 enzyme, which indicates pharmacokinetic interaction present between DSN and CBZ. Diosmin 111-114 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 37-43 27690733-14 2017 The results suggest that the altered CYP3A4 enzyme activity and pharmacokinetics of CBZ might be attributed to DSN-mediated inhibition of CYP3A4 enzyme, which indicates pharmacokinetic interaction present between DSN and CBZ. Diosmin 111-114 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 138-144 27690733-14 2017 The results suggest that the altered CYP3A4 enzyme activity and pharmacokinetics of CBZ might be attributed to DSN-mediated inhibition of CYP3A4 enzyme, which indicates pharmacokinetic interaction present between DSN and CBZ. Diosmin 213-216 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 37-43 27690733-14 2017 The results suggest that the altered CYP3A4 enzyme activity and pharmacokinetics of CBZ might be attributed to DSN-mediated inhibition of CYP3A4 enzyme, which indicates pharmacokinetic interaction present between DSN and CBZ. Diosmin 213-216 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 138-144 28738538-12 2017 The TNF-alpha level in hippocampus of the diosmin group was significantly lower than the TBI group (p<0.001). Diosmin 42-49 tumor necrosis factor Rattus norvegicus 4-13 28738538-14 2017 The effects of diosmin may be mediated through a decrement in the TNF-alpha concentration of hippocampus as a pro-inflammatory cytokine. Diosmin 15-22 tumor necrosis factor Rattus norvegicus 66-75 28625489-9 2017 Single treatment with diosmin inhibited in a dose-dependent manner CCI-induced mechanical and thermal hyperalgesia by activating the NO/cGMP/PKG/KATP channel signaling pathway and inhibiting spinal cord cytokine (Il-1beta and Il-33/St2) and glial cells activation (microglia - Iba-1, oligodendrocytes - Olig2) mRNA expression markers. Diosmin 22-29 interleukin 33 Mus musculus 226-231 28625489-9 2017 Single treatment with diosmin inhibited in a dose-dependent manner CCI-induced mechanical and thermal hyperalgesia by activating the NO/cGMP/PKG/KATP channel signaling pathway and inhibiting spinal cord cytokine (Il-1beta and Il-33/St2) and glial cells activation (microglia - Iba-1, oligodendrocytes - Olig2) mRNA expression markers. Diosmin 22-29 induction of brown adipocytes 1 Mus musculus 277-282 28625489-9 2017 Single treatment with diosmin inhibited in a dose-dependent manner CCI-induced mechanical and thermal hyperalgesia by activating the NO/cGMP/PKG/KATP channel signaling pathway and inhibiting spinal cord cytokine (Il-1beta and Il-33/St2) and glial cells activation (microglia - Iba-1, oligodendrocytes - Olig2) mRNA expression markers. Diosmin 22-29 oligodendrocyte transcription factor 2 Mus musculus 303-308 28625489-10 2017 Daily treatment during 7 days with diosmin inhibited CCI-induced mechanical and thermal hyperalgesia by inhibiting spinal cord cytokine (Il-1beta, Tnfalpha, and Il-33/St2) and glial cells activation (astrocytes - Gfap, Iba-1, and Olig2) markers mRNA expression. Diosmin 35-42 interleukin 1 beta Mus musculus 137-145 28625489-10 2017 Daily treatment during 7 days with diosmin inhibited CCI-induced mechanical and thermal hyperalgesia by inhibiting spinal cord cytokine (Il-1beta, Tnfalpha, and Il-33/St2) and glial cells activation (astrocytes - Gfap, Iba-1, and Olig2) markers mRNA expression. Diosmin 35-42 tumor necrosis factor Mus musculus 147-155 28625489-10 2017 Daily treatment during 7 days with diosmin inhibited CCI-induced mechanical and thermal hyperalgesia by inhibiting spinal cord cytokine (Il-1beta, Tnfalpha, and Il-33/St2) and glial cells activation (astrocytes - Gfap, Iba-1, and Olig2) markers mRNA expression. Diosmin 35-42 interleukin 33 Mus musculus 161-166 28625489-10 2017 Daily treatment during 7 days with diosmin inhibited CCI-induced mechanical and thermal hyperalgesia by inhibiting spinal cord cytokine (Il-1beta, Tnfalpha, and Il-33/St2) and glial cells activation (astrocytes - Gfap, Iba-1, and Olig2) markers mRNA expression. Diosmin 35-42 glial fibrillary acidic protein Mus musculus 213-217 28625489-10 2017 Daily treatment during 7 days with diosmin inhibited CCI-induced mechanical and thermal hyperalgesia by inhibiting spinal cord cytokine (Il-1beta, Tnfalpha, and Il-33/St2) and glial cells activation (astrocytes - Gfap, Iba-1, and Olig2) markers mRNA expression. Diosmin 35-42 induction of brown adipocytes 1 Mus musculus 219-224 28625489-10 2017 Daily treatment during 7 days with diosmin inhibited CCI-induced mechanical and thermal hyperalgesia by inhibiting spinal cord cytokine (Il-1beta, Tnfalpha, and Il-33/St2) and glial cells activation (astrocytes - Gfap, Iba-1, and Olig2) markers mRNA expression. Diosmin 35-42 oligodendrocyte transcription factor 2 Mus musculus 230-235 27151911-13 2017 The results suggest that altered pharmacokinetics of FEX might be attributed to DSN-mediated inhibition of P-gp-mediated efflux in humans. Diosmin 80-83 phosphoglycolate phosphatase Homo sapiens 107-111 28177765-0 2017 Diosmin attenuates radiation-induced hepatic fibrosis by boosting PPAR-gamma expression and hampering miR-17-5p-activated canonical Wnt-beta-catenin signaling. Diosmin 0-7 peroxisome proliferator-activated receptor gamma Rattus norvegicus 66-76 28177765-0 2017 Diosmin attenuates radiation-induced hepatic fibrosis by boosting PPAR-gamma expression and hampering miR-17-5p-activated canonical Wnt-beta-catenin signaling. Diosmin 0-7 catenin beta 1 Rattus norvegicus 136-148 28177765-5 2017 Also, the effect of Dios on hepatic peroxisome proliferator activated receptor-gamma (PPAR-gamma) expression as a regulator for HSC activation was considered. Diosmin 20-24 peroxisome proliferator-activated receptor gamma Rattus norvegicus 36-84 28177765-5 2017 Also, the effect of Dios on hepatic peroxisome proliferator activated receptor-gamma (PPAR-gamma) expression as a regulator for HSC activation was considered. Diosmin 20-24 peroxisome proliferator-activated receptor gamma Rattus norvegicus 86-96 28177765-7 2017 RESULTS: Data analysis revealed that Dios treatment mitigated oxidative stress, enhanced antioxidant defenses, alleviated hepatic inflammatory responses, abrogated pro-fibrogenic cytokines, and stimulated PPAR-gamma expression. Diosmin 37-41 peroxisome proliferator-activated receptor gamma Rattus norvegicus 205-215 28177765-8 2017 Dios treatment repressed the miR-17-5p activated Wnt-beta-catenin signaling induced by IRR. Diosmin 0-4 catenin beta 1 Rattus norvegicus 53-65 28665324-10 2017 Repeated treatment of STZ-diabetic rats with diosmin for one week induced changes in hepatic glycogen, lipid levels, and the expression of phosphoenolpyruvate carboxykinase (PEPCK). Diosmin 45-52 phosphoenolpyruvate carboxykinase 1 Rattus norvegicus 139-172 28665324-10 2017 Repeated treatment of STZ-diabetic rats with diosmin for one week induced changes in hepatic glycogen, lipid levels, and the expression of phosphoenolpyruvate carboxykinase (PEPCK). Diosmin 45-52 phosphoenolpyruvate carboxykinase 1 Rattus norvegicus 174-179 28218955-8 2017 Repeated treatment of STZ-diabetic rats with diosmin for 1 week resulted in an increase in the expression of the glucose transporter subtype 4 (GLUT 4) in the soleus muscle and a reduction in the expression of phosphoenolpyruvate carboxykinase (PEPCK) in the liver. Diosmin 45-52 solute carrier family 2 member 4 Rattus norvegicus 113-142 28218955-8 2017 Repeated treatment of STZ-diabetic rats with diosmin for 1 week resulted in an increase in the expression of the glucose transporter subtype 4 (GLUT 4) in the soleus muscle and a reduction in the expression of phosphoenolpyruvate carboxykinase (PEPCK) in the liver. Diosmin 45-52 solute carrier family 2 member 4 Rattus norvegicus 144-150 28218955-8 2017 Repeated treatment of STZ-diabetic rats with diosmin for 1 week resulted in an increase in the expression of the glucose transporter subtype 4 (GLUT 4) in the soleus muscle and a reduction in the expression of phosphoenolpyruvate carboxykinase (PEPCK) in the liver. Diosmin 45-52 phosphoenolpyruvate carboxykinase 1 Rattus norvegicus 210-243 28218955-8 2017 Repeated treatment of STZ-diabetic rats with diosmin for 1 week resulted in an increase in the expression of the glucose transporter subtype 4 (GLUT 4) in the soleus muscle and a reduction in the expression of phosphoenolpyruvate carboxykinase (PEPCK) in the liver. Diosmin 45-52 phosphoenolpyruvate carboxykinase 1 Rattus norvegicus 245-250 27151911-14 2017 Therefore, we conclude that intake of DSN or dietary supplements containing DSN may potentially increase the absorption or bioavailability of FEX, a P-gp substrate in humans. Diosmin 38-41 phosphoglycolate phosphatase Homo sapiens 149-153 27151911-14 2017 Therefore, we conclude that intake of DSN or dietary supplements containing DSN may potentially increase the absorption or bioavailability of FEX, a P-gp substrate in humans. Diosmin 76-79 phosphoglycolate phosphatase Homo sapiens 149-153 28819543-1 2017 The current study was designed to investigate the beneficial role of diosmin, a biologically active flavonoid, against methotrexate- (MTX-) induced hepatic, renal, and cardiac injuries in mice. Diosmin 69-76 metaxin 1 Mus musculus 134-137 27890807-0 2017 Diosmin-induced senescence, apoptosis and autophagy in breast cancer cells of different p53 status and ERK activity. Diosmin 0-7 tumor protein p53 Homo sapiens 88-91 27890807-0 2017 Diosmin-induced senescence, apoptosis and autophagy in breast cancer cells of different p53 status and ERK activity. Diosmin 0-7 mitogen-activated protein kinase 1 Homo sapiens 103-106 27890807-4 2017 Diosmin caused G2/M cell cycle arrest, elevation in p53, p21 and p27 levels and stress-induced premature senescence when used at lower concentrations (5 and 10muM). Diosmin 0-7 tumor protein p53 Homo sapiens 52-55 27890807-4 2017 Diosmin caused G2/M cell cycle arrest, elevation in p53, p21 and p27 levels and stress-induced premature senescence when used at lower concentrations (5 and 10muM). Diosmin 0-7 H3 histone pseudogene 16 Homo sapiens 57-60 27890807-4 2017 Diosmin caused G2/M cell cycle arrest, elevation in p53, p21 and p27 levels and stress-induced premature senescence when used at lower concentrations (5 and 10muM). Diosmin 0-7 interferon alpha inducible protein 27 Homo sapiens 65-68 27890807-5 2017 Diosmin (20muM) also promoted apoptosis that was not observed in normal human mammary epithelial cells (HMEC). Diosmin 0-7 latexin Homo sapiens 11-14 28819543-5 2017 Additionally, both diosmin doses significantly reduced tissue levels of malondialdehyde and nitric oxide and increased those of glutathione, glutathione peroxidase, glutathione reductase, glutathione S-transferase, superoxide dismutase, and catalase, compared to the MTX-intoxicated group. Diosmin 19-26 catalase Mus musculus 241-249 28819543-5 2017 Additionally, both diosmin doses significantly reduced tissue levels of malondialdehyde and nitric oxide and increased those of glutathione, glutathione peroxidase, glutathione reductase, glutathione S-transferase, superoxide dismutase, and catalase, compared to the MTX-intoxicated group. Diosmin 19-26 metaxin 1 Mus musculus 267-270 28819543-6 2017 Histopathological examination showed that diosmin significantly minimized the MTX-induced histological alterations and nearly restored the normal architecture of hepatic, renal, and cardiac tissues. Diosmin 42-49 metaxin 1 Mus musculus 78-81 28819543-7 2017 Based on these findings, diosmin may be a promising agent for protection against MTX-induced cytotoxicity in patients with cancer and autoimmune diseases. Diosmin 25-32 metaxin 1 Homo sapiens 81-84 28819543-4 2017 Diosmin treatment ameliorated the MTX-induced elevation of serum alkaline phosphatase, aminotransferases, urea, creatinine, lactate dehydrogenase, and creatine kinases as well as plasma proinflammatory cytokines (interleukin-1-beta, interleukin-6, and tumor necrosis factor-alpha). Diosmin 0-7 metaxin 1 Mus musculus 34-37 28819543-4 2017 Diosmin treatment ameliorated the MTX-induced elevation of serum alkaline phosphatase, aminotransferases, urea, creatinine, lactate dehydrogenase, and creatine kinases as well as plasma proinflammatory cytokines (interleukin-1-beta, interleukin-6, and tumor necrosis factor-alpha). Diosmin 0-7 interleukin 1 beta Mus musculus 213-231 28819543-4 2017 Diosmin treatment ameliorated the MTX-induced elevation of serum alkaline phosphatase, aminotransferases, urea, creatinine, lactate dehydrogenase, and creatine kinases as well as plasma proinflammatory cytokines (interleukin-1-beta, interleukin-6, and tumor necrosis factor-alpha). Diosmin 0-7 interleukin 6 Mus musculus 233-246 28819543-4 2017 Diosmin treatment ameliorated the MTX-induced elevation of serum alkaline phosphatase, aminotransferases, urea, creatinine, lactate dehydrogenase, and creatine kinases as well as plasma proinflammatory cytokines (interleukin-1-beta, interleukin-6, and tumor necrosis factor-alpha). Diosmin 0-7 tumor necrosis factor Mus musculus 252-279 28819543-5 2017 Additionally, both diosmin doses significantly reduced tissue levels of malondialdehyde and nitric oxide and increased those of glutathione, glutathione peroxidase, glutathione reductase, glutathione S-transferase, superoxide dismutase, and catalase, compared to the MTX-intoxicated group. Diosmin 19-26 glutathione reductase Mus musculus 165-186 28819543-5 2017 Additionally, both diosmin doses significantly reduced tissue levels of malondialdehyde and nitric oxide and increased those of glutathione, glutathione peroxidase, glutathione reductase, glutathione S-transferase, superoxide dismutase, and catalase, compared to the MTX-intoxicated group. Diosmin 19-26 hematopoietic prostaglandin D synthase Mus musculus 188-213 27422995-7 2016 Furthermore, Pearson correlation analysis showed that vitreous fibulin-1 was correlated with SBP, DBP, high-density lipoprotein cholesterol and serum fibulin-1. Diosmin 98-101 fibulin 1 Homo sapiens 63-72 27980660-10 2016 Similarly, the pathway-based 2-locus epistasis analysis indicated significant interactions between INSR and PRKCG for SBP and MAP; INS and PIK3R2 for DBP; PIK3CD and ATP1B2 for hypertension in the real data set. Diosmin 150-153 phosphoinositide-3-kinase regulatory subunit 2 Homo sapiens 139-145 27492452-0 2016 Diosmin Modulates the NF-kB Signal Transduction Pathways and Downregulation of Various Oxidative Stress Markers in Alloxan-Induced Diabetic Nephropathy. Diosmin 0-7 nuclear factor kappa B subunit 1 Rattus norvegicus 22-27 27492452-13 2016 Moreover, oral administration of diosmin shows a significant normalization in the level of NF-kB, proving its pivotal role in maintaining renal function. Diosmin 33-40 nuclear factor kappa B subunit 1 Rattus norvegicus 91-96 27725131-0 2016 Diosmin reduces cerebral Abeta levels, tau hyperphosphorylation, neuroinflammation, and cognitive impairment in the 3xTg-AD mice. Diosmin 0-7 amyloid beta (A4) precursor protein Mus musculus 25-30 27725131-1 2016 Naturally-occurring bioactive flavonoids such as diosmin significantly reduces amyloid beta (Abeta) associated pathology in Alzheimer"s disease (AD) mouse models. Diosmin 49-56 amyloid beta (A4) precursor protein Mus musculus 93-98 27725131-2 2016 In the present study, oral administration of diosmin reduced cerebral Abeta oligomer levels, tau-hyperphosphorylation and cognitive impairment in the 3xTg-AD mouse model through glycogen synthase kinase-3 (GSK-3) and transient receptor potential canonical 6-related mechanisms. Diosmin 45-52 amyloid beta (A4) precursor protein Mus musculus 70-75 27725131-2 2016 In the present study, oral administration of diosmin reduced cerebral Abeta oligomer levels, tau-hyperphosphorylation and cognitive impairment in the 3xTg-AD mouse model through glycogen synthase kinase-3 (GSK-3) and transient receptor potential canonical 6-related mechanisms. Diosmin 45-52 glycogen synthase kinase 3 beta Mus musculus 178-204 27725131-2 2016 In the present study, oral administration of diosmin reduced cerebral Abeta oligomer levels, tau-hyperphosphorylation and cognitive impairment in the 3xTg-AD mouse model through glycogen synthase kinase-3 (GSK-3) and transient receptor potential canonical 6-related mechanisms. Diosmin 45-52 glycogen synthase kinase 3 beta Mus musculus 206-211 27725131-3 2016 Diosmetin, one major bioactive metabolite of diosmin, increased inhibitory GSK-3beta phosphorylation, while selectively reducing gamma-secretase activity, Abeta generation, tau hyperphosphorylation and pro-inflammatory activation of microglia in vitro, without altering Notch processing. Diosmin 45-52 glycogen synthase kinase 3 beta Mus musculus 75-84 27107807-0 2016 In vitro effects of the citrus flavonoids diosmin, naringenin and naringin on the hepatic drug-metabolizing CYP3A enzyme in human, pig, mouse and fish. Diosmin 42-49 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 108-113 26960804-8 2016 RESULTS: Circulating RBP4 levels were positively associated with BMI, waist circumference, waist-to-hip ratio (WHR), systolic and diastolic (SBP), diastolic blood pressure (DBP), triglycerides (TG), low high-density lipoprotein cholesterol(LDL-c), and testosterone (TESTO) in the total group. Diosmin 173-176 retinol binding protein 4 Homo sapiens 21-25 26728949-7 2016 RESULTS: The participants with serum prokineticin-2 levels >6.32 ng/ml had increased waist circumference, body mass index (BMI), plasma triglyceride, diastolic blood pressure (DBP), blood glucose, and serum uric acid, but decreased age, plasma high-density lipoprotein cholesterol (HDL-C), and HDL-C/total cholesterol (TC) (all P < 0.05). Diosmin 179-182 prokineticin 2 Homo sapiens 37-51 26759608-7 2016 A 1 % increase in HbA1 was associated with 1.73 mmHg increase in DBP. Diosmin 65-68 hemoglobin subunit alpha 1 Homo sapiens 18-22 25582650-5 2016 In general linear regression model, TG/HDL-C was an independent determinant of CIMT even after adjusting for BMI, SBP, DBP, TG, TC, LDL-C, HDL-C, HbA1c and HOMA-IR. Diosmin 119-122 CIMT Homo sapiens 79-83 26880195-8 2016 The largest alteration of SBP related to the temperature difference was observed from 20.4 to 9.6 C, with 9.0 mmHg (95 % CI: 8.4, 9.5) increase in SBP, while the largest alteration of DBP was observed from 21.7 to 10.2 C, with 6.1 mmHg (95 % CI: 5.6, 6.6) increase in DBP. Diosmin 185-188 selenium binding protein 1 Homo sapiens 26-29 26880195-8 2016 The largest alteration of SBP related to the temperature difference was observed from 20.4 to 9.6 C, with 9.0 mmHg (95 % CI: 8.4, 9.5) increase in SBP, while the largest alteration of DBP was observed from 21.7 to 10.2 C, with 6.1 mmHg (95 % CI: 5.6, 6.6) increase in DBP. Diosmin 270-273 selenium binding protein 1 Homo sapiens 26-29 26448026-10 2015 Adropin had a negative correlation with DBP (r = -0.40, P < 0.001), SBP (r = -0.49, P < 0.001), and adjusted for age, body mass index, SBP, DBP, glucose, TC, TG, LDL, and Cr, there was a negative correlation between ET-1 and adropin (r = -0.20, P = 0.04). Diosmin 40-43 energy homeostasis associated Homo sapiens 0-7 26361726-9 2015 Diosmin treatment showed a substantial reduction in T cell (CD4(+) and CD8(+)) receptors and pro-inflammatory (IL-2(+) and IL-17(+)) cytokines in whole blood. Diosmin 0-7 interleukin 2 Mus musculus 111-115 26361726-9 2015 Diosmin treatment showed a substantial reduction in T cell (CD4(+) and CD8(+)) receptors and pro-inflammatory (IL-2(+) and IL-17(+)) cytokines in whole blood. Diosmin 0-7 interleukin 17A Mus musculus 123-128 26361726-10 2015 In addition, RT-PCR analysis revealed increased mRNA expression of IL-6, IL-17, TNF-alpha, and NF-kappaB in the LPS group, while reduced by treatment with diosmin. Diosmin 155-162 interleukin 6 Mus musculus 67-71 26361726-10 2015 In addition, RT-PCR analysis revealed increased mRNA expression of IL-6, IL-17, TNF-alpha, and NF-kappaB in the LPS group, while reduced by treatment with diosmin. Diosmin 155-162 interleukin 17A Mus musculus 73-78 26361726-10 2015 In addition, RT-PCR analysis revealed increased mRNA expression of IL-6, IL-17, TNF-alpha, and NF-kappaB in the LPS group, while reduced by treatment with diosmin. Diosmin 155-162 tumor necrosis factor Mus musculus 80-89 26361726-11 2015 Western blot analysis confirmed the increased protein expression of IL-1beta, TNF-alpha and NF-kappaB p65 in the LPS group and treatment of animals with diosmin reversed these effects. Diosmin 153-160 interleukin 1 beta Mus musculus 68-76 26361726-11 2015 Western blot analysis confirmed the increased protein expression of IL-1beta, TNF-alpha and NF-kappaB p65 in the LPS group and treatment of animals with diosmin reversed these effects. Diosmin 153-160 tumor necrosis factor Mus musculus 78-87 26361726-11 2015 Western blot analysis confirmed the increased protein expression of IL-1beta, TNF-alpha and NF-kappaB p65 in the LPS group and treatment of animals with diosmin reversed these effects. Diosmin 153-160 v-rel reticuloendotheliosis viral oncogene homolog A (avian) Mus musculus 102-105 26448026-10 2015 Adropin had a negative correlation with DBP (r = -0.40, P < 0.001), SBP (r = -0.49, P < 0.001), and adjusted for age, body mass index, SBP, DBP, glucose, TC, TG, LDL, and Cr, there was a negative correlation between ET-1 and adropin (r = -0.20, P = 0.04). Diosmin 146-149 energy homeostasis associated Homo sapiens 0-7 25712660-1 2015 BACKGROUND: Diosmin is a natural flavone glycoside, a potent P-glycoprotein (P-gp) inhibitor in cultured cells and have the potential to alter the bioavailability of P-gp substrate drugs. Diosmin 12-19 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 61-75 25712660-1 2015 BACKGROUND: Diosmin is a natural flavone glycoside, a potent P-glycoprotein (P-gp) inhibitor in cultured cells and have the potential to alter the bioavailability of P-gp substrate drugs. Diosmin 12-19 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 77-81 25712660-1 2015 BACKGROUND: Diosmin is a natural flavone glycoside, a potent P-glycoprotein (P-gp) inhibitor in cultured cells and have the potential to alter the bioavailability of P-gp substrate drugs. Diosmin 12-19 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 166-170 25712660-9 2015 CONCLUSIONS: Diosmin significantly enhanced the oral bioavailability of fexofenadine by the inhibition of P-gp mediated drug efflux during the intestinal absorption. Diosmin 13-20 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 106-110 25499067-8 2015 The more robust recruitment of 53BP1 was correlated with lower DNA and chromosomal damage after naringin and hesperidin treatment compared with diosmin treatment. Diosmin 144-151 tumor protein p53 binding protein 1 Homo sapiens 31-36 23886889-2 2013 The interactions of diosmin to human serum albumin have been investigated by fluorescence, UV-visible, FTIR spectroscopy, native electrophoresis and protein-ligand docking studies. Diosmin 20-27 albumin Homo sapiens 43-50 25760167-5 2015 In men, HBP was statistically associated with high body mass index (BMI) and tile floor in the home (as a socioeconomic proxy); BMI and WC were associated with SBP; BMI and WC were associated with DBP. Diosmin 197-200 heme binding protein 1 Homo sapiens 8-11 25192491-7 2014 Serum PTH levels were positively correlated with DBP (r=0.256, p=0.010) and HbA1c (r=0.223, p=0.003), while not being related to other risk factors of CHD (all p>0.05). Diosmin 49-52 parathyroid hormone Homo sapiens 6-9 24680937-0 2014 Diosmin protects against cerebral ischemia/reperfusion injury through activating JAK2/STAT3 signal pathway in mice. Diosmin 0-7 Janus kinase 2 Mus musculus 81-85 24680937-0 2014 Diosmin protects against cerebral ischemia/reperfusion injury through activating JAK2/STAT3 signal pathway in mice. Diosmin 0-7 signal transducer and activator of transcription 3 Mus musculus 86-91 24374742-5 2014 Variants at three published loci (GC, DHCR7, CYP2R1, and CYP24A1) for 25(OH)D, were not significantly associated with BP, but rs6013897 in CYP24A1 gene region had nominally significant associations with both SBP and DBP (P < 0.05). Diosmin 216-219 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 139-146 24126178-9 2013 Patients who entered the trial with a SBP >= 140 mm Hg at baseline obtained a significant reduction of 15 mm Hg in SBP and 7 mm Hg in DBP from flaxseed ingestion. Diosmin 137-140 selenium binding protein 1 Homo sapiens 38-41 23402272-0 2013 Diosmin protects against trichloroethylene-induced renal injury in Wistar rats: plausible role of p53, Bax and caspases. Diosmin 0-7 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 98-101 24036254-7 2013 Also, diosmin inhibited the enhanced activity of liver HMG CoA reductase. Diosmin 6-13 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 55-72 23402272-7 2013 Co-treatment with DM prevented oxidative stress by restoring the levels of antioxidant enzymes; furthermore, a significant dose-dependent decrease in DNA disintegration and kidney toxicity markers such as blood urea N, creatinine, lactate dehydrogenase and kidney injury molecule-1 was observed. Diosmin 18-20 hepatitis A virus cellular receptor 1 Rattus norvegicus 257-281 23402272-0 2013 Diosmin protects against trichloroethylene-induced renal injury in Wistar rats: plausible role of p53, Bax and caspases. Diosmin 0-7 BCL2 associated X, apoptosis regulator Rattus norvegicus 103-106 23402272-0 2013 Diosmin protects against trichloroethylene-induced renal injury in Wistar rats: plausible role of p53, Bax and caspases. Diosmin 0-7 caspase 9 Rattus norvegicus 111-119 23665045-3 2013 In the present study, we have shown that diosmin attenuates 2-AAF induced hepatic toxicity and early tumor promotion markers (ODC, PCNA and Ki67), its chemopreventive efficacy against DEN initiated and 2-AAF promoted hyper-proliferation and hepatocarcinogenesis in Wistar rats. Diosmin 41-48 ornithine decarboxylase 1 Rattus norvegicus 126-129 23665045-3 2013 In the present study, we have shown that diosmin attenuates 2-AAF induced hepatic toxicity and early tumor promotion markers (ODC, PCNA and Ki67), its chemopreventive efficacy against DEN initiated and 2-AAF promoted hyper-proliferation and hepatocarcinogenesis in Wistar rats. Diosmin 41-48 proliferating cell nuclear antigen Rattus norvegicus 131-135 23665045-3 2013 In the present study, we have shown that diosmin attenuates 2-AAF induced hepatic toxicity and early tumor promotion markers (ODC, PCNA and Ki67), its chemopreventive efficacy against DEN initiated and 2-AAF promoted hyper-proliferation and hepatocarcinogenesis in Wistar rats. Diosmin 41-48 antigen identified by monoclonal antibody Ki 67 Mus musculus 140-144 23665045-5 2013 Protective efficacy of diosmin has been investigated in terms of its potential in reducing the percentage of visible hepatic nodules and the restoration of early tumor markers (PCNA, Ki67 and ODC), oxidative stress biomarkers, serum cytotoxicity markers (AST, ALT and LDH), cell necrosis markers (NF-kappa B and TNF-alpha) and inflammatory markers (COX-2 and iNos). Diosmin 23-30 proliferating cell nuclear antigen Mus musculus 177-181 23665045-5 2013 Protective efficacy of diosmin has been investigated in terms of its potential in reducing the percentage of visible hepatic nodules and the restoration of early tumor markers (PCNA, Ki67 and ODC), oxidative stress biomarkers, serum cytotoxicity markers (AST, ALT and LDH), cell necrosis markers (NF-kappa B and TNF-alpha) and inflammatory markers (COX-2 and iNos). Diosmin 23-30 antigen identified by monoclonal antibody Ki 67 Mus musculus 183-187 23665045-5 2013 Protective efficacy of diosmin has been investigated in terms of its potential in reducing the percentage of visible hepatic nodules and the restoration of early tumor markers (PCNA, Ki67 and ODC), oxidative stress biomarkers, serum cytotoxicity markers (AST, ALT and LDH), cell necrosis markers (NF-kappa B and TNF-alpha) and inflammatory markers (COX-2 and iNos). Diosmin 23-30 ornithine decarboxylase, structural 1 Mus musculus 192-195 23637907-10 2013 All of these effects of diosmin were associated with increased zonular occluden-1 (ZO-1) and occludin protein expression and decreased VEGF/PEDF ratio. Diosmin 24-31 vascular endothelial growth factor A Rattus norvegicus 135-139 23541215-5 2013 The aim of this study was to investigate whether diosmin and diosmetin could inhibit the growth of MRSA and the in vitro enzymatic activity of a newly discovered MRSA drug target, pyruvate kinase (PK). Diosmin 49-56 AT695_RS09030 Staphylococcus aureus 180-195 23541215-5 2013 The aim of this study was to investigate whether diosmin and diosmetin could inhibit the growth of MRSA and the in vitro enzymatic activity of a newly discovered MRSA drug target, pyruvate kinase (PK). Diosmin 49-56 AT695_RS09030 Staphylococcus aureus 197-199 23637907-10 2013 All of these effects of diosmin were associated with increased zonular occluden-1 (ZO-1) and occludin protein expression and decreased VEGF/PEDF ratio. Diosmin 24-31 serpin family F member 1 Rattus norvegicus 140-144 21993364-6 2012 Among non-Hispanic blacks, the D allele was significantly associated (P < 0.05) with increased SBP in additive and dominant covariate-adjusted models and was also associated with increased DBP in dominant models when participants taking ACE inhibitors were excluded from the analyses. Diosmin 192-195 angiotensin I converting enzyme Homo sapiens 240-243 23419394-0 2013 Diosmin protects against ethanol-induced hepatic injury via alleviation of inflammation and regulation of TNF-alpha and NF-kappaB activation. Diosmin 0-7 tumor necrosis factor Rattus norvegicus 106-115 23419394-8 2013 Diosmin administration (D1 & D2) significantly (p < 0.001) attenuates oxidative stress markers i.e., LPO, GSH, GPx, GR and XO by 90.77 & 137.55%, 17.18 & 25%, 37.3 & 49.86%, 21.63 & 44.9% and 56.14 &77.19% respectively. Diosmin 0-7 lactoperoxidase Rattus norvegicus 108-111 23419394-11 2013 Diosmin further alleviated ethanol-induced NF-kappaB activation, enhanced expression of TNF-alpha, COX-2 and iNOS. Diosmin 0-7 tumor necrosis factor Rattus norvegicus 88-97 23419394-11 2013 Diosmin further alleviated ethanol-induced NF-kappaB activation, enhanced expression of TNF-alpha, COX-2 and iNOS. Diosmin 0-7 cytochrome c oxidase II, mitochondrial Rattus norvegicus 99-104 23419394-11 2013 Diosmin further alleviated ethanol-induced NF-kappaB activation, enhanced expression of TNF-alpha, COX-2 and iNOS. Diosmin 0-7 nitric oxide synthase 2 Rattus norvegicus 109-113 22289577-5 2012 Diosmin showed strong HA22T cell viability inhibition in a dose dependent manner and significantly reduced the cell proliferative proteins as well as inducing cell cycle arrest in the G2/M phase through p53 activation and PI3K-Akt-MDM2 signaling pathway inhibition. Diosmin 0-7 MDM2 proto-oncogene Homo sapiens 231-235 22289577-6 2012 However, protein phosphatase 2A (PP2A) siRNA or PP2A inhibitor totally reversed the diosmin effects. Diosmin 84-91 protein phosphatase 2 phosphatase activator Homo sapiens 33-37 22289577-6 2012 However, protein phosphatase 2A (PP2A) siRNA or PP2A inhibitor totally reversed the diosmin effects. Diosmin 84-91 protein phosphatase 2 phosphatase activator Homo sapiens 48-52 22289577-7 2012 The HA22T-implanted nude mice model further confirmed that diosmin inhibited HA22T tumor cell growth and down regulated the PI3K-Akt-MDM2 signaling and cell cycle regulating proteins, as well as activating PP2A and p53 proteins. Diosmin 59-66 AKT serine/threonine kinase 1 Homo sapiens 129-132 22289577-7 2012 The HA22T-implanted nude mice model further confirmed that diosmin inhibited HA22T tumor cell growth and down regulated the PI3K-Akt-MDM2 signaling and cell cycle regulating proteins, as well as activating PP2A and p53 proteins. Diosmin 59-66 MDM2 proto-oncogene Homo sapiens 133-137 22289577-7 2012 The HA22T-implanted nude mice model further confirmed that diosmin inhibited HA22T tumor cell growth and down regulated the PI3K-Akt-MDM2 signaling and cell cycle regulating proteins, as well as activating PP2A and p53 proteins. Diosmin 59-66 protein phosphatase 2 phosphatase activator Homo sapiens 206-210 22289577-7 2012 The HA22T-implanted nude mice model further confirmed that diosmin inhibited HA22T tumor cell growth and down regulated the PI3K-Akt-MDM2 signaling and cell cycle regulating proteins, as well as activating PP2A and p53 proteins. Diosmin 59-66 tumor protein p53 Homo sapiens 215-218 22289577-8 2012 Our findings indicate that HA22T cell proliferation inhibition and tumor growth suppression by diosmin are mediated through PP2A activation. Diosmin 95-102 protein phosphatase 2 phosphatase activator Homo sapiens 124-128 22509733-8 2012 RESULTS: Diosmin significantly decreased the MDA levels and increased the activities of T-SOD, GSH-Px, and CAT in the retina of rats compared with the ischemia group (P<0.05), and suppressed the I/R-induced reduction in the a- and b-wave amplitudes of the ERG (P<0.05). Diosmin 9-16 glutathione peroxidase 1 Rattus norvegicus 95-101 22509733-8 2012 RESULTS: Diosmin significantly decreased the MDA levels and increased the activities of T-SOD, GSH-Px, and CAT in the retina of rats compared with the ischemia group (P<0.05), and suppressed the I/R-induced reduction in the a- and b-wave amplitudes of the ERG (P<0.05). Diosmin 9-16 catalase Rattus norvegicus 107-110 22289577-5 2012 Diosmin showed strong HA22T cell viability inhibition in a dose dependent manner and significantly reduced the cell proliferative proteins as well as inducing cell cycle arrest in the G2/M phase through p53 activation and PI3K-Akt-MDM2 signaling pathway inhibition. Diosmin 0-7 tumor protein p53 Homo sapiens 203-206 22289577-5 2012 Diosmin showed strong HA22T cell viability inhibition in a dose dependent manner and significantly reduced the cell proliferative proteins as well as inducing cell cycle arrest in the G2/M phase through p53 activation and PI3K-Akt-MDM2 signaling pathway inhibition. Diosmin 0-7 AKT serine/threonine kinase 1 Homo sapiens 227-230 21228793-8 2011 One SNP (rs11638762), in the GATA-3 binding site upstream of the AKAP13 gene, was significantly replicated in another cohort (P-value of the meta-analysis = 1.4 x 10(-5) for systolic blood pressure and 6.3 x 10(-4) for DBP). Diosmin 219-222 GATA binding protein 3 Mus musculus 29-35 21477647-3 2011 In this study, we investigated the possible protective and anti-inflammatory mechanisms of diosmin, a natural flavone glycoside, on LPS-induced PC12 cells death through inhibition of TNF-alpha production. Diosmin 91-98 tumor necrosis factor Rattus norvegicus 183-192 21477647-5 2011 Diosmin significantly increased cells survival and suppressed LPS-induced TNF-alpha in a concentration-dependent manner. Diosmin 0-7 tumor necrosis factor Rattus norvegicus 74-83 21477647-6 2011 Diosmin also significantly reduced the DNA fragmentation of LPS-induced cells, and its anti-apoptotic effect was confirmed by the decrease in the expression of pro-apoptotic protein Bad and the increase in the expression of anti-apoptotic protein Bcl-2 on Western blot analysis. Diosmin 0-7 BCL2, apoptosis regulator Rattus norvegicus 247-252 21477647-7 2011 Furthermore, diosmin inhibited LPS-induced caspase-3 activation further confirming its anti-apoptotic effects. Diosmin 13-20 caspase 3 Rattus norvegicus 43-52 21477647-8 2011 This is the first study to report the anti-inflammatory and anti-apoptotic effects of diosmin via inhibition of TNF-alpha and a caspase-dependent pathway in neuronal PC12 cells. Diosmin 86-93 tumor necrosis factor Rattus norvegicus 112-121 21228793-8 2011 One SNP (rs11638762), in the GATA-3 binding site upstream of the AKAP13 gene, was significantly replicated in another cohort (P-value of the meta-analysis = 1.4 x 10(-5) for systolic blood pressure and 6.3 x 10(-4) for DBP). Diosmin 219-222 A kinase (PRKA) anchor protein 13 Mus musculus 65-71 17676865-0 2007 Effects of diosmin, a flavonoid glycoside in citrus fruits, on P-glycoprotein-mediated drug efflux in human intestinal Caco-2 cells. Diosmin 11-18 ATP binding cassette subfamily B member 1 Homo sapiens 63-77 19766327-4 2009 The current study investigated the effects of luteolin, a citrus bioflavonoid, and its structural analog, diosmin, on IL-6 induced JAK2/STAT3 (Janus tyrosine kinase-2/signal transducer and activator of transcription-3) phosphorylation and signaling as well as behavioral phenotypes of MIA offspring. Diosmin 106-113 interleukin 6 Homo sapiens 118-122 19766327-4 2009 The current study investigated the effects of luteolin, a citrus bioflavonoid, and its structural analog, diosmin, on IL-6 induced JAK2/STAT3 (Janus tyrosine kinase-2/signal transducer and activator of transcription-3) phosphorylation and signaling as well as behavioral phenotypes of MIA offspring. Diosmin 106-113 Janus kinase 2 Homo sapiens 131-135 19766327-4 2009 The current study investigated the effects of luteolin, a citrus bioflavonoid, and its structural analog, diosmin, on IL-6 induced JAK2/STAT3 (Janus tyrosine kinase-2/signal transducer and activator of transcription-3) phosphorylation and signaling as well as behavioral phenotypes of MIA offspring. Diosmin 106-113 signal transducer and activator of transcription 3 Homo sapiens 136-141 19766327-4 2009 The current study investigated the effects of luteolin, a citrus bioflavonoid, and its structural analog, diosmin, on IL-6 induced JAK2/STAT3 (Janus tyrosine kinase-2/signal transducer and activator of transcription-3) phosphorylation and signaling as well as behavioral phenotypes of MIA offspring. Diosmin 106-113 signal transducer and activator of transcription 3 Homo sapiens 143-217 19766327-6 2009 Importantly, our results showed that diosmin (10mg/kgday) was able to block the STAT3 signal pathway; significantly opposing MIA-induced abnormal behavior and neuropathological abnormalities in MIA/adult offspring. Diosmin 37-44 signal transducer and activator of transcription 3 Homo sapiens 80-85 18045723-6 2008 PBMI, CBMI, SBP and DBP were significantly higher in the DM2 than N. G was higher in DM2 and IGT. Diosmin 34-37 immunoglobulin heavy diversity 1-14 (non-functional) Homo sapiens 71-74 19245142-16 2008 CONCLUSION: Administration of semisynthetic diosmin during 30 days results in significant improvement of clinical signs, quality of life and CEAP stage of HVI. Diosmin 44-51 biogenesis of lysosomal organelles complex 1 subunit 2 Homo sapiens 141-145 19326773-13 2008 All bioflavonoids, i.e., quercetin, diosmin, methyl hesperidin, gossypin and chrysin, decreased the transport of nitrendipine, a P-gp substrate in the rat intestine. Diosmin 36-43 phosphoglycolate phosphatase Rattus norvegicus 129-133 19326774-13 2008 Diosmin might have inhibited the microsomal CYP2E1-mediated hydroxylation of chlorazoxazone. Diosmin 0-7 cytochrome P450 family 2 subfamily E member 1 Homo sapiens 44-50 19918004-12 2010 In addition, maternal ABP, particularly DBP, was closely related to ACR in the offspring, suggesting a dominant effect of maternal genes or an effect of the intrauterine environment on microalbuminuria risk. Diosmin 40-43 acrosin Homo sapiens 68-71 23964162-5 2009 Female patients receiving Daflon( ) either alone or with oral hypoglycemic showed significant decrease in serum glucose; fructosamine; total cholesterol; LDL-cholesterol; triglycerides; malondialdehydes (as index of lipid peroxidation) and C-reactive protein (CRB) levels along with increase in the levels of nitric oxide and blood glutathione. Diosmin 26-32 C-reactive protein Homo sapiens 240-258 17676865-7 2007 These results demonstrated that diosmin effectively inhibited the P-gp-mediated efflux in Caco-2 cells. Diosmin 32-39 ATP binding cassette subfamily B member 1 Homo sapiens 66-70 17676865-8 2007 Diosmin is one of the main components in citrus fruits, and the intake of food supplements containing this compound may potentially increase the absorption of drugs able to act as P-gp substrates. Diosmin 0-7 ATP binding cassette subfamily B member 1 Homo sapiens 180-184 17708066-11 2007 Diosmin might have inhibited the microsomal CYP2C9 mediated oxidation of diclofenac sodium. Diosmin 0-7 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 44-50 17159770-6 2006 Moreover, synthetic beta-naphthoflavone and naturally occurring chrysin, quercetin and diosmin induced CYP1A1 in both tissues. Diosmin 87-94 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 103-109 17053765-1 2006 The study was held to assess clinical effectiveness of coaggregated semisynthetic Diosmin (Phlebodia 600) for patients with II-III CEAP classes of chronic venous insufficiency (CVI), caused by lower limb variceal diseases. Diosmin 82-89 biogenesis of lysosomal organelles complex 1 subunit 2 Homo sapiens 131-135